IP Library › Granted Patent US 7,547,718
Granted Patent B2
US 7,547,718 · App. 11/945,064 · Granted Jun 16, 2009

Substituted imidazoles

Assignee: Pfizer Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,547,718
App. No.
11/945,064
Granted
Jun 16, 2009
Kind
B2
Abstract

This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.

Claims (68)

1. A method of treating a parasite infestation in a mammal comprising treating the host animal with an effective amount of a compound of formula (I)

wherein:

R 1 , R 2 , R 3 , R 4 , R 5 are independently selected from the group consisting of hydrogen, cyano, nitro, halo, hydroxy, C 1-4 alkyl optionally substituted by one or more hydroxy groups, or C 3-6 cycloalkyl which is further optionally substituted by one or more C 1-4 alkyl or halo groups, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, phenyl, amino, NR x R y , or S(O) n R 10 ;

R 6 is selected from the group consisting of hydrogen, —C 0-2 alkyleneR 7 , —C 1-2 alkyleneOR 7 , —C 0-2 alkyleneC(O)R 7 , —C 1-2 alkyleneOC(O)R 7 , —C 1-2 alkyleneOC(O)OR 7 , —C 0-2 alkyleneC(O)OR 7 , —C 1-2 alkyleneN(H)C(O)R 7 , —C 1-2 alkyleneN(R 7 )C(O)R 7 , —C 0-2 alkyleneC(O)NHR 7 , —C 0-2 alkyleneC(O)NR 15 R 16 , —C 1-2 alkyleneNHC(O)NR 15 R 16 , —C 1-2 alkyleneNR 7 C(O)NR 15 R 16 , —C 1-2 alkyleneOC(O)NHR 7 , —C 1-2 alkyleneOC(O)NR 15 R 16 , —C 0-2 alkyleneCH═N(R 7 ), —C 1-2 alkyleneP(═O)(NR 15 R 16 )(NR 15 R 16 ), —C 0-2 alkyleneSi(R 7 ) 3 , and —C 0-2 alkyleneS(O)R 10 ;

where the C 0-2 alkylene or C 1-2 alkylene of R 6 may, where chemically possible, optionally be substituted by one or more substituents selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, C 1-4 alkylene(C 3-6 cycloalkyl), C 0-6 alkylenephenyl, which C 0- 2 alkylene or C 1-2 alkylene substituent may in turn be optionally further substituted, where chemically possible, by one or more substituents selected from the group consisting of hydrogen, cyano, nitro, halo, formyl, oxo, hydroxy, C(O)OH, C 1-4 alkyl, C 1-4 alkyleneC 3-6 cycloalkyl, C 1-4 alkoxy, C 1-4 alkyleneC 1-4 alkyoxy, —C(O)OC 1-4 alkyl, C 1-4 haloalkyl, C 1-4 haloalkoxy, amino, C 1-4 alkylamino, C 1-4 dialkylamino, and S(O) n R 10 ;

where each R 7 , R 15 and R 16 , where chemically possible, is independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 1-4 alkylene(C 3-6 cycloalkyl), C 1-4 alkyleneC 1-4 alkoxy, C 1-6 haloalkyl, C 0-6 alkylenephenyl, C 0-6 alkylenenaphthyl, C 0-6 alkylene(tetrahydronaphthyl), and C 0-2 alkylene(Het), where Het is selected from oxetanyl, tetrahydropyranyl, piperidinyl, morpholinyl, furyl, pyridyl, benzofuranyl, benzothiazolyl, indolyl, 2,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolyl and 1,5-naphthyridinyl;

or R 15 and R 16 together with the nitrogen to which they are attached may form a three to seven-membered saturated or unsaturated heterocyclic ring optionally containing one or more further N, O or S atoms or SO 2 groups;

where each of the above R 7 , R 15 or R 16 groups may independently include one or more optional substituents where chemically possible selected from hydrogen, cyano, nitro, halo, formyl, oxo, hydroxy, C(O)OH, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 1-4 alkyleneC 3-6 cycloalkyl, C 1-4 alkoxy, C 1-4 alkyleneC 1-4 alkyoxy, C 1-4 alkoxyC 1-4 alkoxy, C 1-4 alkanoyl, —C(O)OC 1-4 alkyl, C 1-4 haloalkyl, C 3-6 halocycloalkyl, C 1-4 haloalkoxy, C 1-4 haloalkanoyl, —C(O)OC 1-4 haloalkyl, phenyl, 4-halophenyl, 4-alkoxyphenyl, 2-cyanophenyl, phenoxy, 4-halophenoxy, benzyloxy, 4-halobenzyloxy, benzoyl, pyrazolyl, triazolyl, 2-halo-4-pyrimidinyl, 2-phenylethyl, amino, C 1-4 alkylamino, C 1-4 dialkylamino, C(O)N(C 1-4 alkyl) 2 , N(C 1-4 alkylene)C(O)(C 1-4 alkyl) and S(O) n R 10 ;

R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy and C 0-4 alkylenephenyl but with the proviso that R 8 and R 9 are not both hydrogen;

where each of R 8 and R 9 may independently include one or more optional substituents where chemically possible selected from hydrogen, cyano, halo, hydroxy, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-4 alkoxy, —C(O)OC 1-4 alkyl, C 1-4 haloalkyl, C 1-4 haloalkoxy, and S(O) n R 10 ;

or R 8 and R 9 together with the carbon to which they are attached may form a three to six membered carbocyclic, saturated ring, which ring is optionally substituted with one or more substituents selected from the group consisting of halo, C 1-2 alkyl, C 1-2 alkoxy, C 1-2 haloalkyl, C 1-2 haloalkoxy;

R 11 and R 12 are independently selected from the group consisting of hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, and C 1-4 haloalkoxy;

where R x and R y are independently selected from hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, and S(O) n R 10 ;

each n is independently 0, 1 or 2;

and each R 10 is independently hydrogen, hydroxy, C 1-4 alkyl, C 1-4 haloalkyl, 4-halophenyl, amino, C 1-6 alkyl amino and di C 1-6 alkyl amino; or a pharmaceutically acceptable salt thereof.

2. A method of claim 1 wherein in the compound of formula (I) R 1 and R 2 are methyl; and R 3 , R 4 , and R 5 are hydrogen.

3. A method of claim 1 wherein in the compound of formula (I) R 6 is hydrogen, —C 0-2 alkyleneR 7 , or —C 1-2 alkyleneOC(O)R 7 .

4. A method of claim 3 wherein in the compound of formula (I) R 6 is hydrogen, 2,2-dimethylpropionyloxymethyl, propionyloxymethyl, 3-cyclopentylpropionyloxy- methyl, 3-methylbutyryloxymethyl, heptanoyloxymethyl, butyryloxymethyl, pentanoyloxymethyl, phenylmethyl, 4-methoxybenzyloxycarbonyloxymethyl, cyclopropylmethyl, methyl, cyclopropylmethyloxycarbonyloxymethyl, 3-methylbutoxycarbonyloxymethyl, isopropoxycarbonyloxymethyl, cyclobutoxycarbonyloxymethyl, 2,2,2-trifluoroethyloxycarbonyloxymethyl, ethyl, 4-methoxybenzyl, methoxymethyl, 4-(trifluoromethyl)benzyl, isobutoxycarbonyl, or isopropoxycarbonyl.

5. A method of claim 1 wherein in the compound of formula (I) R 8 is methyl and R 9 is hydrogen.

6. A method of claim 1 wherein in the compound of formula (I) R 11 and R 12 are hydrogen.

7. A method of claim 1 wherein the compound of formula (I) is selected from a compound of formula (IA) and formula (IB)

wherein R 3 , R 4 , R 5 , R 6 , R 11 and R 12 are hydrogen.

8. A method of claim 7 wherein R 1 , R 2 and R 6 are methyl; and R 9 is hydrogen.

9. A method of claim 8 wherein the compound of formula (I) is

10. A method of claim 8 wherein the compound of formula (I) is

11. A method of claim 1 wherein the compound of formula (I) is selected from:

2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;

2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;

2-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;

{2-[1-(2,3-dimethylphenyl)ethy]-1H-imidazol1-yl}methylpivalate;

{2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1 -yl}methylpivalate;

{2-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methylpivalate;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol- 1-yl}methylpropionate;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methyl3-methylbutanoate;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methylbutyrate;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methyl 3-cyclopentylpropanoate;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methylheptanoate;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methylpentanoate;

2-{1-[2-(trifluoromethyl)phenyl]ethyl}-1H-imidazole;

2-[1-(2,5-dimethylphenyl)ethyl]-1H-imidazole;

2-[1-(4-chloro-3-methylphenyl)ethyl]-1H-imidazole;

2-[1-(3,5-dimethylphenyl)ethyl]-1H-imidazole;

1-benzyl-2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methyl4-methoxybenzylcarbonate;

1-(cyclopropymethyl)-2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;

2-1-(2,3-dimethylphenyl)ethyl]-1-methyl-1H-imidazole;

cyclopropylmethyl {2-1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methylcarbonate;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methyl 3-methylbutylcarbonate;

{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methylcarbonate;

cyclobutyl{2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methyl carbonate;

2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-yl}methyl 2,2,2-trifluoroethylcarbonate;

2-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl-1H-imidazole;

2-[1-(2,3-dimethylphenyl)ethyl]-1-(4-methoxybenzyl)-1H-imidazole;

2-[1-(2,3-dimethylphenyl)ethyl]-1-(methoxymethyl)- 1H-imidazole;

2-[1-(2,3-dimethylphenyl)ethyl]-1-1[4-(trifluoromethyl)benzyl]-1H-imidazole;

4-fluorophenyl 2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylate;

isobutyl 2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylate;

isopropyl 2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylate; an

2-[1-(3-methylphenyl)ethyl]-1H-imidazole;

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 wherein the mammal is an animal, a bird or a fish.

13. The method of claim 12 wherein the mammal is an animal.

14. The method of claim 13 wherein the animal is cats, dogs, horses, cattle, sheep, pigs, goats, equines, or swine.

15. The method of claim 1 wherein the parasite is an insect or acarid.

16. The method of claim 15 wherein the parasite are ticks.

17. The method of treating a parasite infestation of claim 1 is a method of controlling an insect or acarid infestation at a locus.

18. The method of claim 17 comprising applying an effective amount of a compound of formula (I) to said locus.

19. The method of claim 1 wherein the compound of formula (I) is administered orally, parenterally, or topically.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2014
From: PFIZER LIMITED
To: PFIZER ANIMAL HEALTH UK 1 LIMITED
Reel/Frame 032948/0351 →
Continuity (3)
Division 1161973500 · Jan 4, 2007
Provisional Application 6076076500 · Jan 19, 2006
Related Publication 20080125473A1 · May 29, 2008